Immutep enters into collaboration with Pfizer & Merck KGaA
Filed with ASX · · 4 pages · English
Earlier from Immutep
- Progress towards clinical development of IMP761
- Appendix 4E & 2018 Full Year Statutory Accounts
- TACTI-mel Patient Recruitment Complete & Operational Update
- Immutep receives IND approval from US FDA for IMP321
- Immutep submits IND application with FDA
Later from Immutep
- Positive interim TACTI-mel data presented at SITC
- Immutep granted European patent for IMP321
- European patent granted for IMP321 & antibody combinations
- Cleansing prospectus for issue of warrants
- Immutep enters into collaboration with CYTLIMIC
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep